

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028

Status	RECRUITING
Phase	Phase 3
Sponsor	Eli Lilly and Company
Enrollment	4,500 participants

Key Eligibility Criteria

Inclusion (3)

- Have liver fat content e8%
- Have ELF score of e9 and d10.8 at screening
- Have VCTE LSM e10 kilopascal (kPa) and ≤ 20 kPa at screening

Exclusion (6)

- Have any other type of liver disease other than MASLD
 - Have a body mass index (BMI) ≤ 25 kilogram per square meter (kg/m²)
 - Prior decompensated liver disease (history of esophageal/gastric varices, ascites, hepatic encephalopathy)
 - Have lost more than 11 pounds within the 3 months prior to screening
 - Have a hemoglobin A1c (HbA1c) greater than 10%
- ... and 1 more (see full listing online)

Locations (561 total)

MFA Clinical Research, Tuscaloosa, Alabama, United States
The Institute for Liver Health II dba Arizona Clinical Trials - Chandler, Chandler, Arizona, United States
Spectrum Research Institute, Gilbert, Arizona, United States
... and 558 more locations